Prednisolone Acetate ophthalmic suspension recalled for temperature-abuse during distribution
Prednisolone Acetate ophthalmic suspension is being recalled nationwide due to temperature deviations during distribution. McKesson Medical-Surgical has notified affected customers.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard (temperature-induced degradation of the suspension) is theoretical. Per the rubric, FDA Class II without reported hospitalization scores at most 3 when the hazard is theoretical.
Plain-English summary
McKesson Medical-Surgical Inc. is recalling Prednisolone Acetate Ophthalmic Suspension, USP 1% (5 mL bottles) distributed nationwide to U.S. customers. The recall is due to cGMP (current Good Manufacturing Practice) deviations involving temperature abuse during distribution.
Prednisolone acetate is a corticosteroid eye suspension. Temperature exposure during storage and transport can affect the quality and stability of pharmaceutical suspensions.
Consumers and healthcare providers who have received affected product should not use it. Contact McKesson Medical-Surgical or speak with your pharmacist or healthcare provider for replacement product or other guidance.
No illnesses or injuries have been reported to date.
The recalled product
- Product
- PREDNISOLONE ACETATE (PREDNISOLONE ACETATE)
- Brand
- PREDNISOLONE ACETATE
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Ophthalmic Corticosteroid
- Hazard
- temperature-abuse
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01